A Minimum Of 100 Tumor Cells in a Single Biopsy Sample Is Required to Assess Programmed Cell Death Ligand 1 Expression in Predicting Patient Response to Nivolumab Treatment in Nonsquamous Non–Small Cell Lung Carcinoma

IntroductionProgrammed death ligand 1 (PD-L1) expression is a predictive biomarker for patient response to nivolumab in nonsquamous NSCLC. However, the number of biopsy samples and tumor cells (TCs) required to assess PD-L1 expression remains unclear.MethodsA total of 222 biopsy samples from 80 patients with nonsquamous NSCLC treated with nivolumab were collected. Number of TCs and PD-L1 score were compared among the sample containing the largest number of TCs (Max-TC), the sample containing the smallest number of TCs (Min-TC), and the total samples from each patient. The impact of the number of samples and TCs on the prediction of patient response to nivolumab with use of PD-L1 scores was evaluated.ResultsThere was a mismatch in PD-L1 scores less than 1% and those of at least 1% between Max-TC and the total samples in one patient (1%) and between Max-TC and Min-TC in six patients (8%). The optimal number of TCs to match PD-L1 expression less than 1% versus at least 1% between Max-TC and Min-TC was 100 (sensitivity = 0.676 and 1 – specificity = 0.333). PD-L1 expression of at least 1% in Min-TCs containing at least 100 TCs was associated with longer progression-free survival (median 7.6 versus 1.8 months [p < 0.01]) and overall survival (median not reached versus 9.9 months [p = 0.04]) compared with PD-L1 expression less than 1%. However, there were no differences in progression-free survival (median 3.9 versus 2.3 months [p = 0.37]) or overall survival (median 9.7 versus 7.6 months [p = 0.60]) between PD-L1 expression of at least 1% and PD-L1expression less than 1% in Min-TCs containing fewer than 100 TCs.ConclusionSingle biopsy samples containing at least 100 TCs are required to evaluate PD-L1 expression for predicting patient response to nivolumab.     

胃癌前哨淋巴结临床意义的研究

目的 观察胃癌前哨淋巴结的分布，探讨其临床意义。方法 回顾性分析288例胃癌前哨淋巴结术中染色后显影的范围及特征。术中向肿瘤边缘的正常胃壁浆膜下肌层、黏膜下层注射亚甲蓝，观察淋巴结显影的情况；切取各站淋巴结行病理检查。结果 288例胃癌术后病理诊断为T1期102例，T2期126例，T3期60例。术中成功显影270例，阳性率为93．8％。102例患者有淋巴结转移，其中前哨淋巴结（SNs）与非前哨淋巴结（non—SNs）均有转移者66例，仅前哨淋巴结有转移者18例，仅非前哨淋巴结有转移者18例。结论 通过前哨淋巴结，术中能准确预测胃癌淋巴结转移状况。在手术治疗淋巴结转移阴性的胃癌患者中，前哨淋巴结术中标识有望免除常规淋巴清扫。     

经直肠超声引导13点前列腺系统穿刺活检术的并发症及防治

目的探讨经直肠超声引导13点前列腺系统穿刺活检术的并发症及防治措施.方法回顾性分析本组1998年8月至2004年12月336例接受经直肠超声引导13点前列腺穿刺活检术患者的临床资料.结果336例患者中出现的并发症有:血尿218例;血便67例,血精10例,感染10例,明显疼痛(VAS评分大于5分)85例,血管迷走神经反应10例等.结论经直肠超声引导13点前列腺系统穿刺活检术用于诊断前列腺癌常可见小的并发症,大的并发症则很少见.该术式用于诊断前列腺是安全的.     

胸腰椎病变CT监视下穿刺活检路径分析

目的探讨胸腰椎病变CT监视下穿刺活检中穿刺路径的选择方法。方法141例胸腰椎病变临床诊断不清患者，其中胸椎70例，腰椎71例。根据病变位于脊椎的不同部位选择合适的穿刺路径，于CT监视下穿刺取材。穿刺路径：经椎旁路径63例，经椎弓根路径45例，经肋椎关节路径11例，其他路径22例。结果141例中共有128例诊断正确，穿刺结果诊断正确率为90．8％。无并发症发生。结论胸腰椎病变穿刺路径的选择要根据病变的位置不同具体分析。总的原则是安全、取材量多、对患者损伤小。     

Interstitial and vascular pancreas rejection in relation to graft survival

To examine the incidence of interstitial and vascular rejection in pancreas allografts and its impact on graft survival, we studied 36 percutaneous pancreas biopsies and 10 pancreas transplantectomy specimens from 32 patients who had undergone simultaneous pancreas-kidney transplantation. Interstitial rejection (IR) was predominantly found in the biopsies, while vascular rejection (VR) was most prominent in the transplantectomies. Pancreas graft survival was significantly decreased for pancreas grafts that had suffered from vascular rejection when compared to those with only interstitial rejection. Potential rejection markers, i. e., serum amylase, glucose, creatinine, and urinary amylase, did not correlate with histological signs of rejection, although increased levels of serum amylase were, in all but one case, associated with rejection.We conclude that a percutaneous pancreas biopsy remains the most reliable method to determine pancreas rejection, and that by distinguishing between IR andVR, a pancreas biopsy may provide important diagnostic as well as prognostic information. Received: 6 March 1997 Received after revision: 5 June 1997 Accepted: 30 June 1997     

超声引导经皮穿刺活检与CA19-9联合检测对胰腺占位性病变的诊断价值

目的 :探讨超声引导下经皮穿刺活检与CA19 9联合检测对胰腺占位性病变的诊断价值。　方法 :对 30例超声检查怀疑胰腺占位性病变者行血清学CA19 9检测 ,并在体表B超引导下 ,用 18G或 19G切割活检针和 2 2G抽吸活检针行组织学和细胞学检查。　结果 :CA19 9诊断的敏感性为 92 % ,特异性 5 0 % ,准确性 92 %。超声引导经皮穿刺活检 30例患者总穿刺成功率为 93.3% (2 8/ 30 ) ,2 6例胰腺癌患者穿刺成功率为 92 .3% (2 4 / 2 6 ) ,活检阳性者 2 3例 ,其诊断敏感性为 88.4 % ,特异性 10 0 % ,准确性 88.4 %。CA19 9与超声引导经皮穿刺活检联合检测对胰腺占位性病变诊断的敏感性为 92 .3%、特异性 10 0 %、准确性 92 .3% ,与单行超声引导经皮穿刺活检比较有显著差异 (P <0 .0 5 ) ,而且对患者的治疗及预后有指导意义。穿刺结束后除个别患者有轻微腹痛外 ,无一例出现出血、胰瘘及胃穿孔等并发症。　结论 :体表B超引导下经皮穿刺与CA19 9联合检测对胰腺占位性病变诊断的敏感性、特异性、准确性较单一检测高 ,而且对患者的治疗及预后有一定价值 ,是一种安全、可靠的方法。     

235例乳腺病变粗针吸微创性活检及免疫组织化学检测意义

目的评价乳腺病变粗针吸活检（CNB）方法，探讨CNB组织免疫组织化学检测的临床意义。方法对CNB后接受手术治疗的235例乳腺病变病理资料进行分析对比，对其中CNB诊断为浸润性癌后行术前化疗的87例进行p53、c-erbB-2、ER和PR免疫组织化学（SP法）检测，并与观测化疗后癌组织形态学变化结合分析。结果235例中CNB诊为乳腺癌者204例，与手术后病理良恶性符合率为100％；CNB诊为非浸润性癌中60％病例术后病理发现浸润性癌成分；CNB诊为不典型增生者中50％术后病理证实为癌；CNB组织与术后常规组织免疫组织化学表达阳性率一致，差异无统计学意义（P〉0．05）；有、无化疗反应的病例p53、c-erbB-2表达差异有统计学意义（P〈0．05）；p53和c-erBb-2阳性病例多无明显化疗后形态学改变。结论CNB对乳腺病变是一种有效且创伤轻微的诊断方法，但它仍有一定局限性，用CNB组织做免疫组织化学检测有较为重要的临床意义。     

Sarcomas of head and neck — A 10 yrs experience

38 cases of sarcoma of head and neck region were analysed in a retrospective way in relation to age, anatomic location, histological, clinical profile, and surgical approaches. Compared to other types of head and neck neoplasms, such as squamous cell carcinoma, soft tissue sarcomas have low rates of regional metastases. However the biological behaviour of soft tissue sarcoma is more aggressive specially in paediatric age group. In the present series, CT scan was considered as the primary modality of investigation. Surgery generally has been recommended as the primary method of treatment for achieving local control, except in those high-grade tumours arising in sites not amenable to resection. 3-year and 5-year survival rates in this present series 50% and 31.6% respectively.     

对IgM肾病的探讨

50例肾活检的原发性肾小球肾炎中,发现6例IgM肾病。主要病理特点为系膜增殖及IgM荧光沉积。临床表现以肾病综合征为特点,血清IgM升高,蛋白尿及血尿,并呈高凝状态。